Loading clinical trials...

Observing People With Desmoid-Type Fibromatosis | Clinical Trials | Clareo Health

RECRUITING

Observing People With Desmoid-Type Fibromatosis

A Prospective Analysis of Active Observation in Patients With Desmoid-Type Fibromatosis

NCT04281381•Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

The purpose of this study is to closely observe people with desmoid-type fibromatosis over 1 months.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Clinical diagnosis of desmoid fibromatosis, either new or newly recurrent. Both patients with sporadic and FAP-associated disease will be eligible for inclusion. Patients with clinical diagnosis of desmoid (as assessed by MSK physician) but without pathologic diagnosis may be enrolled on the study to facilitate acquisition of appropriately protocoled baseline scans and allow for biospecimen collection; these patients will be replaced for purposes of analysis if pathology does not confirm clinical diagnosis.
•At least 18 years of age.
•Able to undergo cross-sectional imaging by either MRI or CT with intravenous contrast
•Disease detectable on cross-sectional imaging with target lesion measuring \>/= 1 cm
•Eligible for management by active observation as assessed by primary MSK care provider
•Willing and able to sign an informed consent document

Exclusion Criteria

•Symptomatic desmoid fibromatosis requiring narcotic pain control, resulting in intestinal fistulization, or requiring inpatient admission during the 3 months prior to enrollment
•Patients with intraabdominal desmoids greater than 7cm in diameter or localized within 1cm of the central mesenteric vessels and those with tumors in the head and neck
•KPS performance status \</= 70 if performance status is limited due to tumor. Patients with low KPS performance status related to co-morbidities but without symptoms related to the tumor will be eligible for enrollment.
•Age less than 18 years old
•Strict contraindication for both cross-sectional MRI and CT imaging with intravenous contrast (e.g., as per standard institutional protocols regarding renal insufficiency or MRI incompatible implanted devices; patients requiring pre-medication to prevent contrast reactions will be eligible for study)
•Unable to grant reliable informed consent
•Ongoing systemic treatment for desmoid fibromatosis

Locations (1)

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Key Dates

Start Date

February 19, 2020

Primary Completion Date

February 19, 2026

Completion Date

February 19, 2026

Last Updated

May 16, 2025

Enrollment

100

ESTIMATED participants

Conditions

Desmoid Fibromatosis

Interventions

Cross-sectional imaging

DIAGNOSTIC_TEST

Contacts

Aimee M Crago, MD, PhD

CONTACT

212-639-4807 cragoa@mskcc.org

Meera Hameed, MBBS

CONTACT

212-639-7959 hameedm@mskcc.org

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119

Colorectal CarcinomaEndometrial Carcinoma+20 more

View study

COMPLETEDPHASE3

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

NCT02066181

Desmoid Fibromatosis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 16, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions